Specifically, research into the cellular mechanism of sEH targeting offers the possibility of developing strategies that pharmacologically manipulate the subcellular distribution of sEH by mimicking the effect of the R287Q mutation and ultimately improving stroke outcomes. The gene discussed is EPHX2; the disease is stroke disorder.